Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

(2017) J. D. Peyton et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma

(2015) Qian Zhao et al.   HUMAN PATHOLOGY

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

(2015) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors

(2015) R Gopalakrishnan et al.   ONCOGENE

Constitutive NF-κB Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma

(2015) Francesco Turturro   Biomed Research International

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma

(2015) Laia Rosich et al.   Oncotarget

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia

(2015) Jacky Wong et al.   Oncotarget

FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- B to promote survival of human B cells

(2014) M. van Keimpema et al.   BLOOD

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53

(2014) J.-F. Fecteau et al.   BLOOD

Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program

(2014) Chi Young Ok et al.   CANCER

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo

(2014) M. Rahmani et al.   CLINICAL CANCER RESEARCH

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma

(2014) S. E. Trabucco et al.   CLINICAL CANCER RESEARCH

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma

(2014) Zhen Ying Gan et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium

(2014) Danelle F. James et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

(2014) Yiqing Qu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia

(2014) N Sandhöfer et al.   LEUKEMIA

NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

(2014) Lina Odqvist et al.   MODERN PATHOLOGY

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

(2014) D. Chiron et al.   Cancer Discovery

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

(2013) Tahamtan Ahmadi et al.   CANCER

Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1

(2013) David Chiron et al.   CELL CYCLE

Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes

(2013) A. Moros et al.   CLINICAL CANCER RESEARCH

Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy

(2013) Anna Kaisa Pasanen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

BIM-Mediated Membrane Insertion of the BAK Pore Domain Is an Essential Requirement for Apoptosis

(2013) Kathrin Weber et al.   Cell Reports

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

(2012) Ling-Hua Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1

(2012) Chuanbing Zang et al.   CANCER LETTERS

SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma

(2012) Shih-Chuan Hsiao et al.   HISTOPATHOLOGY

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

(2012) S-S Wenzel et al.   LEUKEMIA

The role of phosphatidylinositol 3-kinase-  in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

(2011) S. E. M. Herman et al.   BLOOD

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)

(2011) Prashant Bavi et al.   JOURNAL OF PATHOLOGY

Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in theCCND1gene locus

(2011) Teresa Vela-ChÁvez et al.   LEUKEMIA & LYMPHOMA

Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study

(2010) F. Jardin et al.   BLOOD

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

(2010) Dinis Pedro Calado et al.   CANCER CELL

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

(2010) P M Bhende et al.   LEUKEMIA

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

(2010) Zhengzi Qian et al.   LEUKEMIA RESEARCH

NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma

(2010) Seong-Su Han et al.   Molecular Cancer

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab

(2009) R. Seki et al.   ANNALS OF ONCOLOGY

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

(2009) D. Chauhan et al.   BLOOD

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

(2009) R. Lapalombella et al.   BLOOD

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

A Subset of CD5– Diffuse Large B-Cell Lymphomas Expresses Nuclear Cyclin D1 With Aberrations at theCCND1Locus

(2008) Mats Ehinger et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE